Duration of dose limiting toxicity (DLT) observation is 28 days
This is an open-label, dose escalation, Phase I study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy in patients with relapsed or refractory multiple myeloma and other hematological malignancies